Literature DB >> 843990

Inhibition of the immune response by rapamycin, a new antifungal antibiotic.

R R Martel, J Klicius, S Galet.   

Abstract

Rapamycin, a new antifungal antibiotic, was found to inhibit the immune response in rats. It totally prevented the development of two experimental immunopathies (experimental allergic encephalomyelitis (EAE) and adjuvant arthritis (AA)) and the formation of humoral (IgE-like) antibody. It was about half as potent as cyclophosphamide in inhibiting EAE. In AA and on antibody formation, rapamycin and cyclophosphamide were about equipotent, whereas methotrexate was more potent. The immunosuppressant activity of rapamycin appears to be related to inhibition of the lymphatic system.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 843990     DOI： 10.1139/y77-007

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN： 0008-4212            Impact factor:   2.273


  96 in total

Review 1.  Advances in the development of immunosuppressive agents in organ transplantation.

Authors:  T Ochiai; K Isono
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

Review 2.  mTOR in health and in sickness.

Authors:  Dritan Liko; Michael N Hall
Journal:  J Mol Med (Berl)       Date:  2015-09-22       Impact factor: 4.599

Review 3.  Natural product discovery: past, present, and future.

Authors:  Leonard Katz; Richard H Baltz
Journal:  J Ind Microbiol Biotechnol       Date:  2016-01-06       Impact factor: 3.346

Review 4.  mTOR signaling in stem and progenitor cells.

Authors:  Delong Meng; Anderson R Frank; Jenna L Jewell
Journal:  Development       Date:  2018-01-08       Impact factor: 6.868

5.  mTOR regulates cell survival after etoposide treatment in primary AML cells.

Authors:  Qing Xu; James E Thompson; Martin Carroll
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

6.  TPT1 (tumor protein, translationally-controlled 1) negatively regulates autophagy through the BECN1 interactome and an MTORC1-mediated pathway.

Authors:  Seong-Yeon Bae; Sanguine Byun; Soo Han Bae; Do Sik Min; Hyun Ae Woo; Kyunglim Lee
Journal:  Autophagy       Date:  2017-02-15       Impact factor: 16.016

Review 7.  Translational Control in Cancer.

Authors:  Nathaniel Robichaud; Nahum Sonenberg; Davide Ruggero; Robert J Schneider
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-07-01       Impact factor: 10.005

Review 8.  Rapalogs and mTOR inhibitors as anti-aging therapeutics.

Authors:  Dudley W Lamming; Lan Ye; David M Sabatini; Joseph A Baur
Journal:  J Clin Invest       Date:  2013-03-01       Impact factor: 14.808

9.  The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer.

Authors:  K Chamie; P M Ghosh; T M Koppie; V Romero; C Troppmann; R W deVere White
Journal:  Am J Transplant       Date:  2008-10-06       Impact factor: 8.086

Review 10.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.